596 Views

Novo Nordisk 

“Market Cap $119.6 B As of May 2014

At a Glance

  • Industry: Pharmaceuticals
  • Founded: 1925
  • Country: Denmark
  • CEO: Lars Rebien Sørensen
  • Website: www.novonordisk.com
  • Employees: 37,978
  • Sales: $14.88 B
  • Headquarters: Bagsv?rd

Forbes Lists

#399 Global 2000

  • #636 in Sales
  • #133 in Profit
  • #1467 in Assets
  • #53 in Market value

#70 Innovative Companies (#87 in 2012)

Profile

Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

“Novo Nordisk History

Behind the Novo Nordisk we know today lies an exciting story that goes back 90 years. It began with the two small Danish companies Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium founded in 1923 and 1925, respectively. The two companies started the production of the revolutionary new drug insulin that had just been discovered by two Canadian scientists.

Building on the past – looking to the future

Since the earliest days, both Nordisk and Novo had focus on the development of products to benefit people with diabetes. Competing intensely with one another, the companies developed into two of the best in their field. When at last they decided to merge in 1989, they created Novo Nordisk. A company that has been expanding rapidly ever since with leading positions within diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.

Today the Novo Nordisk Way shows responsibility to patients, employees, communities and investors.

We will in the future continue to build on the legacy left by the founders of Novo Nordisk and do whatever it takes to change diabetes. Our history tells us it can be done. “

*Information from Forbes.com and Novonordisk.com

**Video published on YouTube by “novonordisk